LY5 is a STAT3 inhibitor with an IC 50 value of 0.5 μM. LY5 induces apoptosis and inhibits STAT3 phosphorylation. LY5 shows antitumor activity in vivo, it can be used for the research of cancer In Vitro LY5 shows inhibition effects to U2OS, RH30 and RD2 cancer cells with IC 50 values of 0.52, 0.55 and 1.39 μM, respectively. LY5 (0.25-1 μM; 16 h) induces apoptosis and inhibits STAT3 phosphorylation in human sarcoma cancer cells. LY5 (0.25-1 μM; 5 h) inhibits STAT3 phosphorylation induced by IL-6. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: RH30 and EW8 cell lines Concentration: 0.25-1 μM Incubation Time: 16 hours Result: Completely inhibited Tyr705 phosphorylation at 0.5 μM and dose-dependently decreased in formation of P-STAT3. In Vivo LY5 (5 mg/kg; i.p. once daily for 21 days) inhibits breast tumor growth in vivo . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Nude mice with MDA-MB-231 cancer cells injection Dosage: 5 mg/kg Administration: Intraperitoneal injection; 5 mg/kg; once daily; for 21 days Result: Suppressed tumor growth and significantly reduced the tumor sizes. IC50& Target:IC50: 0.5 μM (STAT3)